Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia  Jesus F Bermejo-Martin, Raquel Almansa, Marta Martin-Fernandez, Rosario Menendez, Antoni Torres  The Lancet Respiratory Medicine  Volume 5, Issue 12, Pages e35-e36 (December 2017) DOI: 10.1016/S2213-2600(17)30444-7 Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure Immunological profiles described in community-acquired pneumonia Patients were admitted to hospital wards or the ICU,1,2 the ICU only,3,5–8 or a hospital ward only.4 Four studies1,2,5,6 included patients with community-acquired pneumonia of any cause, three studies3,7,8 included patients who developed community-acquired pneumonia during the 2009 global influenza virus pandemic, and one study4 included patients with community-acquired pneumonia caused by Streptococcus pneumoniae. ICU=intensive care unit. APACHE-II=Acute Physiology and Chronic Health Evaluation-II. C3b=C3b complement fragment. Bb=factor B. Th=T-helper cell. TCR=T-cell receptor. TLR=Toll-like receptor. LPS=lipopolysaccharide. MARS1=molecular diagnosis and risk stratificiation of sepsis 1. SRS1=sepsis response signature 1. IL=interleukin. The Lancet Respiratory Medicine 2017 5, e35-e36DOI: (10.1016/S2213-2600(17)30444-7) Copyright © 2017 Elsevier Ltd Terms and Conditions